Biomarker ID | 502 |
PMID | 20028763 |
Year | 2009 |
Biomarker | Genomic Evaluators of Metastatic Prostate Cancer (GEMCaP) [Integrated] |
Biomarker Basis | Expression Based |
Biomolecule | DNA (Gene) |
Source | Tissue |
Subjects | Humans |
Regulation | Differentially Expressed |
Odds Ratio/Hazard Ratio/Relative Risk | NA |
Effect on Pathways | NA |
Experiment | Biochemical recurrence (within 1 year ) Vs No recurrence (24 months) |
Type of Biomarker | Prognostic |
Cohort | All patients had clinical stage pT3 or pT2C. 30 patients were selected who expreienced biochemical reccurance within 1 y of RP and/or had positive lymph nodes identified at the time of surgery. Controls were selcted (n=24) such that they remained disease free for 24 months. |
Senstivity | 67% |
Specificity | 63% |
AUC | NA |
Accuracy | 65% |
Level Of Significance | NA |
Method Used | Array comparative genomic hybridization. |
Clinical | No |
Remarks | 39 BAC-based markers of metastasis to assess recurrence risk in silico for high-risk radical prostatectomy cases. This set of biomarkers, the Genomic Evaluators of Metastatic Prostate Cancer (GEMCaP). INTEGRATED: ur integrated approach involved using a fixed threshold for calling copy number losses (subset of 23 loci) and the floating threshold method for the copy num- ber gains (subset of 16 loci). |
Clinical Trial Number | NA |
Degree Of Validity | Not validated on independent patient dataset |
Technical Name | NA |